Patent Ductus Arteriosus Closure Using a New Device: The Nit-Occlud Device

Gamboa, Ricardo; Mollón, Francisco P.; Ríos-Méndez, Raúl E.; Arroyo, Graciela M.; Fogel, A.; Villa, Daniel M.

doi:10.1016/s1885-5857(07)60178-9

Cited by 11 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Descending aortography was repeated 5 to 15 minutes after device placement. The post-trial residual shunt was classified as follows (as described by Gamboa et al 28 ): trace, if the contrast was slightly opaque at the ductal pulmonary end; mild, if the pulmonary artery was stained without outlining its valve; and moderate, if the whole valvular plane was outlined. The PAP and AP were recorded, and the device was released only when the PDA was closed without shunt or with trace shunt.…”

Section: What the Study Addsmentioning

confidence: 99%

Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure

Duanzhen

Xianyang

et al. 2014

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-No method is available to predict whether patients with patent ductus arteriosus (PDA) and severe pulmonary arterial hypertension (PAH) will show persistent postprocedural PAH (PP-PAH) after PDA closure. This study evaluated the usefulness of trial occlusion for predicting PP-PAH after transcatheter PDA closure in patients with severe PAH. Methods and Results-Trial occlusion was performed in 137 patients (age ≥12 years) with PDA and severe PAH. All patients undergoing trial occlusion had a mean pulmonary artery pressure ≥45 mm Hg, pulmonary:systemic flow (Qp/Qs) ratio >1.5, and pulmonary:systemic resistance (Rp/Rs) ratio <0.7. A total of 135 patients (98%) showing stable hemodynamics during occlusion trial underwent successful device closure. Linear correlation analysis revealed weak or moderate relationships between the baseline and post-trial pulmonary artery pressures and pulmonary:systemic pressure (Pp/Ps) ratios. Patients were followed up for 1 to 10 years (median: 5 years). PP-PAH (systolic pulmonary artery pressure >50 mm Hg by Doppler echocardiography) was detected in 17 patients (13%), who displayed no significant differences in sex and age compared with patients without PP-PAH. According to discriminant analysis, the strongest discriminators between patients with and without PP-PAH were the baseline left ventricular end-diastolic volume and the baseline and post-trial systolic Pp/Ps ratios. In particular, a post-trial systolic Pp/Ps ratio >0.5 correctly classified 100% of the PP-PAH and non-PAH patients. Conclusions-Trial

show abstract

Section: What the Study Addsmentioning

confidence: 99%

Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure

Duanzhen

Xianyang

et al. 2014

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…[7][8][9] Estes podem ser utilizados, inclusive, nas variantes anatômicas mais incomuns. 10 Sem dúvida, a morfologia em janela continua apresentando limitações para sua oclusão, basicamente quando o diâmetro menor do canal supera os 3 mm.…”

Section: Discussionunclassified

Fechamento do Canal Arterial Persistente Tipo Janela Com o Oclusor Septal AMPLATZER®

Peña¹,

Acuña²,

Neves³

et al. 2014

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

“…With an occlusion rate of 91% to 100% and few minor complications (0% to 9%), it has been used in some centres, including in Brazil. [25][26][27][28] The Amplatzer ® Duct Occluder II (ADO II) was developed to occlude channels in smaller children by reducing the introducer profile. It maintained the high occlusion rate of existing devices.…”

Section: Discussionmentioning

confidence: 99%

Fechamento de canais arteriais com o dispositivo Cera PDA Occluder: mais uma boa opção na caixa de ferramentas

Chamié

Simöes

Queiroz

et al. 2012

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Background: The percutaneous closure of a patent ductus arteriosus (PDA) has been considered the treatment of choice by most authors, and several devices with different structural characteristics have been used. The initial experience with the novel Cera TM PDA Occluder is reported. Methods: From March of 2010 through December of 2011, patients weighing over 5 kg with a PDA diagnosed by transthoracic echocardiogram (TTE) with colour Doppler flow mapping and no associated defects underwent the procedure. Follow-up was performed by TTE one, three, and six months after the procedure, and yearly thereafter. Results: Overall, 18 patients were referred for percutaneous occlusion; 61.2% were female. The mean age and weight were 13.7 ± 9.3 years and 42.9 ± 20.1 kg, respectively. Regarding morphology, 11 were type A, six were type E, and one had a residual postoperative defect. The mean diameter was 4.2 mm. Implantation was possible in all patients. Ten 6-4 mm, one 8-6 mm, three 10-8 mm, and four 12-10 mm devices were used. All defects were completely closed by the first follow-up TTE. Deaths or complications were not observed in this series. Conclusions: The Cera TM prosthesis may be used for the occlusion of small or large defects, and delivers to excellent results in children and adults. The procedure is easy, safe, has a high efficacy and low morbidity, and may be an excellent option for the percutaneous closure of a PDA. Due to its flexibility, oversized devices greater than 2 mm should be used.

show abstract

Patent Ductus Arteriosus Closure Using a New Device: The Nit-Occlud Device

Cited by 11 publications

References 14 publications

Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure

Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure

Fechamento do Canal Arterial Persistente Tipo Janela Com o Oclusor Septal AMPLATZER®

Fechamento de canais arteriais com o dispositivo Cera PDA Occluder: mais uma boa opção na caixa de ferramentas

Contact Info

Product

Resources

About

Patent Ductus Arteriosus Closure Using a New Device: The Nit-Occlud Device

Cited by 11 publications

References 14 publications

Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure

Trial Occlusion to Assess the Risk of Persistent Pulmonary Arterial Hypertension After Closure of a Large Patent Ductus Arteriosus in Adolescents and Adults With Elevated Pulmonary Artery Pressure

Fechamento do Canal Arterial Persistente Tipo Janela Com o Oclusor Septal AMPLATZER&#174;

Fechamento de canais arteriais com o dispositivo Cera PDA Occluder: mais uma boa opção na caixa de ferramentas

Contact Info

Product

Resources

About

Fechamento do Canal Arterial Persistente Tipo Janela Com o Oclusor Septal AMPLATZER®

Fechamento de canais arteriais com o dispositivo Cera PDA Occluder: mais uma boa opção na caixa de ferramentas